Web Sify
Follow us on
Sify.com » Topics » Dating
Dating News

BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events
FOR NON-US MEDIA ONLY Patients with metastatic colorectal cancer (mCRC) receiving BIBF 1120* as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6 months which was equivalent to bevacizumab plus mFOLFOX6 in a randomised two arm phase II study enrolling a total of 126 patients. Importantly, only 34.1%